Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Letemovir in preparation of SARS-CoV-2 novel coronavirus inhibitor

A sars-cov-2, coronavirus technology, applied in the field of medicine, can solve problems such as unclear mechanism of action

Inactive Publication Date: 2020-08-11
南京双运生物技术有限公司 +1
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on whether Letermovir can inhibit SARS-CoV-2, and its mechanism of action is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Letemovir in preparation of SARS-CoV-2 novel coronavirus inhibitor
  • Application of Letemovir in preparation of SARS-CoV-2 novel coronavirus inhibitor
  • Application of Letemovir in preparation of SARS-CoV-2 novel coronavirus inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1 Microscale Thermophoresis (MicroscaleThermophoresis, MST) measures the direct binding of Letermovir to the SARS-CoV-2 novel coronavirus S protein RBD region

[0039] 1. Principle

[0040] This technology is based on the thermophoretic phenomenon of biomolecules. MST uses infrared lasers for local heating to cause directional movement of molecules, and then analyzes the directional movement of particles in microscopic temperature gradients through fluorescence. Changes in the size, charge and hydration layer of biomolecules due to binding can be detected.

[0041] 2. Application

[0042] (1) The binding process of the single-chain antibody to the human antigen protein;

[0043] (2) The interaction between small molecule compounds and model proteins;

[0044] (3) Interaction between in vitro synthesized protein and conjugate molecule;

[0045] (4) The itinerary of the three-dimensional helical structure of DNA / RNA molecules;

[0046] (5) The inhibitory e...

Embodiment 2

[0054] Example 2 Letermovir anti-SARS-CoV-2 activity effect in vitro

[0055] 1. Biosafety requirements

[0056] The in vitro anti-SARS-CoV-2 activity evaluation experiment of Letermovir involves virus culture. According to the requirements of the National Health and Medical Commission's "Biosafety Guidelines for Novel Coronavirus Laboratories (Second Edition)", all virus cultures are conducted at Biosafety Level 3 (BSL- 3) In the laboratory. Use virus culture to extract nucleic acid, and the addition of lysing agent or inactivating agent is carried out under the same level of laboratory and protective conditions as virus culture. Nucleic acid detection and other operations after the live virus is inactivated by a reliable method are carried out in a biosafety level two laboratory (BSL-2).

[0057] 2. Experimental environment

[0058] Room temperature: 22°C, relative humidity: 55%.

[0059] 3. Experimental method

[0060] 1. Experimental grouping

[0061] (1) Letermovir ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of Letemovir in preparation of an SARS-CoV-2 novel coronavirus inhibitor. Research finds that the Letemovir can be combined with an RBD region, combined with an ACE-2 receptor, on a spike protein S1 of SARS-CoV-2 novel coronavirus to prevent the virus from entering cells, so that virus replication isinhibited. Therefore, the Letemovir can be used as an inhibitor of the SARS-CoV-2 novel coronavirus, a new thought is provided for preventing and / or treating the SARS-CoV-2 novel coronavirus, a theoretical basis is provided for development of clinical tests, and the Letemovir has important medical research value.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of Letermovir in the preparation of SARS-CoV-2 novel coronavirus inhibitors. Background technique [0002] Highly pathogenic coronavirus infection has become a public health issue of widespread concern in this decade. Such as Severe Acute Respiratory Syndrome (SARS, 2002-2004), Middle East Respiratory Syndrome (MERS, 2012-present), SARS-CoV-2 (COVID-19), each of these diseases has brought serious consequences to human health and economic development. Huge shock. It has been reported that SARS-CoV-2 is a new member of the genus Betacoronavirus (Beta-CoV), which is closely related to severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and several bat coronaviruses. [0003] Since there are no targeted effective drugs and vaccines, the development of new drugs for SARS-CoV-2 is of great significance. In this war without gunpowder, many scientific resea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P31/14
CPCA61K31/517A61P31/14
Inventor 宋世东孙媛媛葛以跃迟莹江经纬
Owner 南京双运生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com